An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects
- 30 April 2004
- journal article
- clinical trial
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 23 (4) , 315-324
- https://doi.org/10.1016/j.ijantimicag.2003.09.020
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical modelJournal of Hospital Infection, 2001
- LinezolidDrugs, 2001
- Glycopeptide Resistance in Staphylococcus aureusJournal of Infection, 2000
- Exorcising Protocol-induced Spirits:Medical Decision Making, 1997
- Intravenous-to-oral antibiotic switch therapyPostgraduate Medicine, 1997
- The comparative efficacy and safety of teicoplanin and vancomycinJournal of Antimicrobial Chemotherapy, 1996
- The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents—a preliminary reportJournal of Hospital Infection, 1995
- In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health CareMedical Care, 1994
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992
- Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibioticsThe American Journal of Medicine, 1991